There is 1 paper on C20:2-OH/C18:2-DC in aging research: 1 trial in people.
1 paper studies it2 findings
See all 1 papers on C20:2-OH/C18:2-DC
- Human trial1
Interventions
1Exercise
downin humans1
1 study
Exercise
downin humans1
Exercise decreases C20:2-OH/C18:2-DC in humans (fold-change 0.7136 vs. 1.741).
“Levels of long-chain acylcarnitine C20:2-OH/C18:2-DC were reduced in the Intervention group by a magnitude of 0.7136 (fold-change) but increased in the Control group by a magnitude of 1.741 (mean difference in fold-change 1.028, p < 0.001, age-adjusted p = 0.004).”
Human trialtwelve weeks
Communications medicine
Exercise decreases C20:2-OH/C18:2-DC in humans (middle-aged adults without cardiovascular disease) (mean difference -1.028, p = 0.004).
“Long-chain acylcarnitine C20:2-OH/C18:2-DC was reduced in the Intervention group by a magnitude of 0.714 but increased in the Control group by a magnitude of 1.742 (mean difference -1.028 age-adjusted p = 0.004).”
Human trialmiddle-aged adults without cardiovascular diseaseserumtwelve weeksfemalesn = 29
Communications medicine
Latest
Communications Medicine
Effects of short-term moderate intensity exercise on the serum metabolome in older adults: a pilot randomized controlled trial
Randomized trial in 30 peopleExercise